The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as "ANGPTL4"), and pharmaceutical compositions and methods of treatment comprising the same.La présente invention concerne des anticorps monoclonaux se liant à la protéine humaine angiopoïétine-like 4 (parfois appelée ("ANGPTL4"), et des compositions pharmaceutiques et des méthodes de traitement comprenant lesdits anticorps.